Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Pathology of COPD
3. Air trapping in COPD
4. New bronchodilators
5. Human small airways: beta2-agonists
6. Indacterol vs. salmeterol in COPD
7. LABA+LAMA combination in COPD
8. Unmet needs in COPD
9. Cellular mechanisms of COPD
10. Treating inflammation in COPD
11. Anti-TNF-alpha in COPD
12. Chemokine receptor antagonists in COPD
13. CXCR2 antagonist in COPD
14. Elastase activity of macrophages in COPD
15. Effect of MMP9 inhibitor on emphysema
16. Broad spectrum anti-inflammatory treatment
17. PDE4 inhibitors in COPD
18. Effect of roflumilast in COPD
19. PDE4 inhibitors: side effects
20. Inhaled PDE inhibitors for COPD
21. p38 MAP kinase inhibitors
22. p38 MAP kinase inhibitors in COPD
23. Major barrier to effective treatment of COPD
24. Amplification and steroid resistance
25. Corticosteroids resistance in COPD
26. Theophylline as HDAC activator
27. How does theophylline restore HDAC?
28. Reversal of corticosteroid resistance
29. Nrf2 and antioxidant gene regulation
30. Sulforaphane increases HDAC2 activity
31. New drugs for COPD

Topics Covered

• New treatments for COPD include long-acting bronchodilators and combinations
• Mediator antagonists, including chemokine antagonists
• Broad-spectrum anti-inflammatory treatments
• Reversal of corticosteroid resistance by increasing HDAC2

Links

Series:

• Advances in Chronic Obstructive Pulmonary Disease (COPD)

Categories:

• Clinical Practice
• Pharmaceutical Sciences

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Publication History

• Published on July 31, 2012

Financial Disclosures

• Peter Barnes receives research grants from AstraZeneca and Boehringer-Ingelheim and is an advisor and/or gives talks for AstraZeneca, Boehringer-Ingelheim, Covis, Novartis, Pieris and Teva.